Detalles de la búsqueda
1.
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Lancet
; 403(10421): 31-43, 2024 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048793
2.
Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 545-550, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38517658
3.
Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology.
Int J Clin Oncol
; 29(5): 535-544, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38494578
4.
Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(4): 355-362, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38353907
5.
Comparison between a single dose of PEG G-CSF and multiple doses of non-PEG G-CSF: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 2024 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38649648
6.
Optimal timing of prophylactic pegylated G-CSF after chemotherapy administration for patients with cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 551-558, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38526621
7.
Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022.
Int J Clin Oncol
; 29(5): 559-563, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38538963
8.
Effectiveness of G-CSF in chemotherapy for digestive system tumors: a systematic review of the Clinical Practice Guidelines for the Use of G-CSF 2022 delineated by the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38578596
9.
Therapeutic use of granulocyte colony-stimulating factor (G-CSF) in patients with febrile neutropenia: a comprehensive systematic review for clinical practice guidelines for the use of G-CSF 2022 from the Japan Society of Clinical Oncology.
Int J Clin Oncol
; 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38696053
10.
Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311).
Int J Gynecol Cancer
; 33(5): 692-700, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36997229
11.
Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial.
Int J Clin Oncol
; 28(1): 163-174, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36534262
12.
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Cancer Sci
; 113(11): 3877-3887, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35792064
13.
Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081.
Gynecol Oncol
; 165(2): 293-301, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35221133
14.
Current trends in chemotherapy for advanced ovarian cancer.
Jpn J Clin Oncol
; 52(8): 806-815, 2022 08 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35521913
15.
A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
Gynecol Oncol
; 162(2): 292-298, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34016453
16.
Utilization and outcomes of adjuvant systemic chemotherapy alone in high risk, early stage cervical cancer in the United States.
Int J Gynecol Cancer
; 31(7): 991-1000, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34016702
17.
A randomized phase III trial of adjuvant chemotherapy versus concurrent chemoradiotherapy for postoperative cervical cancer: Japanese Gynecologic Oncology Group study (JGOG1082).
Int J Gynecol Cancer
; 31(4): 623-626, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33664127
18.
A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer.
Int J Clin Oncol
; 26(10): 1977-1985, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34189636
19.
A retrospective assessment of the safety and efficacy of laparoscopic radical hysterectomy in Japan during the early years following its introduction: a Japanese Gynecologic Oncology Group study (JGOG1081S).
Int J Clin Oncol
; 26(2): 417-428, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33433752
20.
Surveillance of radical hysterectomy for early-stage cervical cancer in the early experienced period of minimally invasive surgery in Japan.
Int J Clin Oncol
; 26(12): 2318-2330, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34435284